Hepatocellular carcinoma in children

Area of Science:

• Hepatology
• Pediatric Oncology
• Public Health

Background:

• Hepatocellular carcinoma (HCC), a frequent human malignancy, can occur in children, particularly those over six years old, with a male predominance.
• High-risk groups for childhood HCC include children with chronic Hepatitis B virus (HBV) infection and underlying metabolic diseases.
• In HBV-hyperendemic regions like Taiwan, HBV infection is the primary cause of childhood HCC, with maternal transmission being the predominant route.

Purpose of the Study:

• To evaluate the impact of universal Hepatitis B virus (HBV) vaccination on childhood Hepatocellular carcinoma (HCC) incidence.
• To assess the effectiveness of HBV immunization as a control strategy for childhood HCC.

Main Methods:

• Analysis of HBV infection prevalence and HCC incidence data in children before and after the implementation of a universal HBV vaccination program.
• Data collected from Taiwan, which launched the world's first universal HBV vaccination program in July 1984.

Main Results:

• The prevalence of hepatitis B surface antigenemia in children under nine years old decreased from 10% in 1984 to less than 1% in 1994.
• The annual incidence of HCC in children aged 6 to 9 years decreased from 0.52 to 0.13 per 100,000 births following the vaccination program's initiation.

Conclusions:

• Universal HBV vaccination is a highly effective strategy for controlling childhood HCC in HBV-hyperendemic areas.
• The Taiwanese HBV vaccination program demonstrated a significant reduction in both HBV infection and HCC incidence among children.